This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Coronavirus Vaccine Development Gathers Steam: 4 Winners
by Ritujay Ghosh
Many biotech companies are coming up with impressive reports on their development of drugs, vaccines and therapies for COVID-19.
Coronavirus Vaccine Race Pushes Up Pharma Giants' Production
by Ritujay Ghosh
Biotech companies and drugmakers are speeding up development of a vaccine for COVID-19. This has seen many big players joining forces to come up with a treatment.
Why Sanofi (SNY) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes? Let's find out.
Is Moderna Winning the COVID-19 Vaccine Race? ETFs to Gain
by Sweta Jaiswal, FRM
Moderna has presented positive interim data from a phase I study evaluating its mRNA-based coronavirus vaccine candidate.
Moderna Rallies on Encouraging Coronavirus Vaccine Study Data
by Zacks Equity Research
Moderna's (MRNA) coronavirus vaccine candidate achieves levels of antibodies similar or higher than those typically found in a patient who recovered from COVID-19 naturally.
5 Biotech Stocks in Focus as Race for Coronavirus Vaccine Heats Up
by Ritujay Ghosh
Drugmakers and biotech companies are initiating development of drugs, vaccines and therapies for COVID-19 and substantial progress has been made over the past month.
Pharma Stock Roundup: FDA Updates for LLY, AZN, MRK, BMY and SNY
by Kinjel Shah
FDA approves Lilly's (LLY) selpercatinib for RET-altered lung and thyroid cancers and AstraZeneca (AZN)/Merck's (MRK) Lynparza for new ovarian cancer use.
The Zacks Analyst Blog Highlights: LLY, AZN, PFE, SNY and BMY
by Zacks Equity Research
The Zacks Analyst Blog Highlights: LLY, AZN, PFE, SNY and BMY
Is Sanofi (SNY) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Sanofi's Blood Disorder Candidate Gets FDA's Priority Review
by Zacks Equity Research
The FDA grants priority review to Sanofi's (SNY) regulatory application for sutimlimab for the treatment of hemolysis in adult patients with cold agglutinin disease (CAD).
Drug Sector Highly Resilient Amid Coronavirus Mayhem: 5 Picks
by Kinjel Shah
Here we highlight five large drugmakers that can be added to one's portfolio amid the coronavirus crisis.
Biotech Companies Lead Search for Coronavirus Vaccine: 4 Winners
by Zacks.com
Although a vaccine is yet to be developed, many companies have already started ramping up manufacturing process of the experimental vaccine candidates they are working on.
Novavax Soars on Coronavirus Vaccine Funding: ETFs to Gain
by Sweta Jaiswal, FRM
Novavax received funding for the coronavirus vaccine and also delivered better-than-expected Q1 results resulting in a stock rally in yesterday's trading session.
Zacks.com featured highlights include: SNY, HTH, RFIL and TPC
by Zacks Equity Research
Zacks.com featured highlights include: SNY, HTH, RFIL and TPC
Boost Portfolio Gains With These 4 Low Price-to-Sales Stocks
by Zacks Equity Research
A stock with a lower price-to-sales ratio is a more suitable investment than a stock with a high price-to-sales ratio.
Esperion (ESPR) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports encouraging first-quarter results. The company records product revenues for the first time during the quarter.
Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates
by Zacks Equity Research
Novo Nordisk (NVO) beats on Q1 sales and earnings, and maintains outlook amid the coronavirus pandemic.
The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Regeneron Pharmaceuticals, Moderna and Sanofi
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Regeneron Pharmaceuticals, Moderna and Sanofi
5 Stocks to Buy as Coronavirus Vaccine in Human Trails Ramp Up
by Zacks Equity Research
As drug makers race to develop vaccine to fight coronavirus, we shortlist five stocks that are poised to grow on progress in clinical trials.
Coronavirus Vaccine Efforts to Aid Moderna (MRNA) Q1 Earnings?
by Zacks Equity Research
Moderna (MRNA) is progressing with coronavirus vaccine development. While grants for development are expected to have aided revenues, increased clinical activity is expected to have increased expenses.
Why Sanofi (SNY) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes? Let's find out.
Regeneron's (REGN) Q1 Earnings & Sales Surpass Estimates
by Zacks Equity Research
Regeneron (REGN) beats on Q1 earnings and sales on solid performance of ophthalmology drug, Eylea; asthma drug, Dupixent; and oncology drug, Libtayo.
Emergent (EBS) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Emergent's (EBS) earnings and revenues surpass estimates in the first quarter of 2020. The company reaffirms its guidance for the ongoing year.
The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Sanofi, GlaxoSmithKline and Moderna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Sanofi, GlaxoSmithKline and Moderna
SNY vs. NVO: Which Stock Is the Better Value Option?
by Zacks Equity Research
SNY vs. NVO: Which Stock Is the Better Value Option?